Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDPC-CDMC)

项目摘要 慢性胰腺炎、糖尿病和糖尿病研究联盟成功的关键是 胰腺癌（联盟）在于有效的沟通和合作， 多学科的科学家;用于发现和验证生物标志物的强大研究设计 慢性胰腺炎（CP），糖尿病（DM）， 和胰腺癌（PDAC），并评估新的干预策略;稳健和高- 高质量的数据和标本收集;以及严格的研究执行财团合作 协议.在过去的四年半里，协调和数据管理中心 （CDMC）提供了强大的科学，行政，监管，管理，后勤， 为联盟提供分析支持，成功启动三个纵向队列 研究（即，PROCEED、INSPPIRE 2和NOD），旨在了解 CP、DM和PDAC之间的关系;以及另外两项研究（即，DETECT和DEPICT（计划中）） 旨在更好地定义和表征3c型糖尿病（T3 cDM）。未来五年， CDMC的总体目标是进一步完善和优化该中心久经考验的基础设施， 运营程序和组织结构，以提供强大和持续的 支持联盟现有的和新的研究，并解决任何新出现的 与研究从累积阶段到以下阶段的进展相关的挑战- 推广和传播阶段。具体而言，我们的目标是（i）提供运作和协调 （二）提供支持，以继续增加和随访患者， 财团批准的研究;（iii）为生物标志物开发提供基础设施， 预防研究和治疗试验;以及（iv）设计和支持新的研究和疾病 预防

Project Summary A key to the success of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (Consortium) lies in effective communication and collaboration among scientists in multiple disciplines; strong study design for discovery and validation of biomarkers characterizing complex interactions between chronic pancreatitis (CP), diabetes mellitus (DM), and pancreatic cancer (PDAC), and evaluation of novel intervention strategies; robust and high- quality data and specimen collection; and rigorous study execution of Consortium collaborative protocols. In the last four and a half years, the Coordination and Data Management Center (CDMC) has provided strong scientific, administrative, regulatory, managerial, logistic, and analytic supports to the Consortium, enabling the successful launch of three longitudinal cohort studies (i.e., PROCEED, INSPPIRE 2, and NOD) that aim to understand the relationship between CP, DM, and PDAC; and two other studies (i.e., DETECT and DEPICT (in planning)) that aim to better define and characterize Type 3c diabetes (T3cDM). In the next five years, the overall CDMC aim is to further refine and optimize the center's time-tested infrastructure, operations procedures, and organizational structure to provide strong and continual supports to the Consortium's existing and new studies, and address any emerging challenges associated with the progress of the studies from the accrual phase to the follow- up and dissemination phases. Specifically, we aim to (i) provide operation and coordination of the Consortium; (ii) provide supports to continue the accrual and follow up of patients in Consortium-approved studies; (iii) provide the infrastructure for biomarker development, prevention studies, and therapeutic trials; and (iv) design and support new studies and disease prevention.